Gary Patou, M.D.
San Francisco Office
Dr. Gary Patou currently serves as an MPM Advisor and Chief Medical Officer (CMO) at Blade Therapeutics and Head of Clinical at Chiasma, both MPM portfolio companies. He has also previously served as CMO at various MPM portfolio companies, including Pacira Pharmaceuticals, Peplin and True North Therapeutics. He played a leading role in gaining FDA approvals for both Pacira’s EXPAREL™ and Peplin’s PICATO™.
Prior to joining MPM, Gary was Executive Vice President and CMO of Oscient Pharmaceuticals, following its merger with GeneSoft Pharmaceuticals. As President of GeneSoft, he was instrumental in applying for and obtaining FDA approval of the company’s lead product, FACTIVE®. Before GeneSoft, Gary worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline, as Senior Vice President and Director, Project and Portfolio Management, managing all of the company’s pharmaceutical development projects including FACTIVE®, as well as FDA-approved products Paxil® and Augmentin®. Prior to this, he served as Director and Vice President of Anti-Infective Development and managed the development of a broad line of anti-infective products. Gary has held several academic appointments at University College and Middlesex School of Medicine in London and is a member of the University of California, San Francisco Clinical and Translational Science Institute Catalyst Program.
Gary received his Medical and Medical Ph.D. degrees from University College, London.